Identification of FDA-approved pharmaceuticals capable of preventing
Alzheimer's disease 
   Lead Investigator:    Anatoly Mayburd
   Institution      :    AMI-GO-SCIENCE
   E-Mail           :    mail@inventomika.org
   Proposal ID      :    851



   Proposal Description:
   The goal of the project is to screen the FDA approved drugs that target the gene products involved in the mechanism of Alzheimer's disease but applied for different purposes. The result of the project will be a list of FDA-approved ligands capable of preventing the onset of Alzheimer's disease.  The project is intended as screening of existing FDA-approved ligands for prophylaxis or delay of Alzheimer's disease.   The targets associated with Alzheimer's or possibly associated will be collated in a single data-set and reorganized in a network model.   The drugs will be mapped on the high-score clusters in the network.  The mapped drugs will be screened by population data and the statistical positives (delaying disease) will be analyzed in neuroprotection and possibly anti-aging experimental setting.   Ideally, in Phase II, combinations of the novel repurposed agents identified in our experiments will be tested in pre-clinical setting.  The purpose of this data extraction is to obtain a positive control at population level. ARBs are known to delay Alzheimer's disease onset although the data is inconsistent as to the extent. Also, we would like to go through the methodology of such studies and introduce refinements based on the feedback from NACC.